白蛋白紫杉醇对比多西他赛在三阴性乳腺癌新辅助治疗中的疗效分析

Efficacy Analysis of Albumin Paclitaxel Versus Docetaxel in Neoadjuvant Treatment of Triple-Negative Breast Cancer

目的探讨在进行三阴性乳腺癌患者的新辅助化疗时,选择白蛋白紫杉醇联合表柔比星以及环磷酰胺进行化疗的效果,分析其临床可应用价值。方法便利选取2018年1月—2020年7月该院收治的68例乳腺癌患者为研究对象,根据治疗方案分组,每组34例。对照组采用常规化疗方案治疗,研究组患者则在对照组的治疗基础上,去除多西他赛,给予白蛋白紫杉醇进行化疗,治疗后,对比两组对患者的ORR和不良反应。结果治疗后,研究组ORR为79.41%,对照组患者治疗ORR为55.88%,差异有统计学意义(χ^(2)=4.300,P=0.038)。研究组患者不良反应发生率为38.24%,对照组患者不良反应发生率35.29%,两组比较差异无统计学意义(χ^(2)=0.063,P=0.801)。结论白蛋白紫杉醇联合表柔比星与环磷酰胺治疗乳腺癌效果确切,值得应用。

Objective To explore the effect of chemotherapy with albumin-paclitaxel combined with epirubicin and cyclophosphamide in neoadjuvant chemotherapy for triple-negative breast cancer patients,and to analyze its clinical application value.Methods Conveniently selected 68 breast cancer patients with admitted the hospital from January 2018to July 2020 as the study objects and divided into 34 patients in each group according to the treatment plan.The control group was treated with conventional chemotherapy,and on the basis of the treatment of the control group,the patients in the study group deleted docetaxel,and were given albumin paclitaxel for chemotherapy.After treatment,the ORR and adverse reactions were compared between the two groups.Results After treatment,ORR of the patients in the study group was 79.41%,higher than the ORR of the patients in the control group was 55.88%,the difference was statistically significant(χ^(2)=4.300,P=0.038).The incidence of the study group was 38.24%,and the incidence of the control group was 35.29%,the difference was not statistically significant between the two groups(χ^(2)=0.063,P=0.801).Conclusion Albumin-paclitaxel combined with epirubicin and cyclophosphamide in the treatment of breast cancer is effective and worthy of application.